

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4540345

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JOHANNES LAURENZ KELLENBERGER	07/25/2015
JURG DREIER	07/25/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BASILEA PHARMACEUTICA AG
<b>Street Address:</b>	GRENZACHERSTRASSE 487
<b>City:</b>	BASEL
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	CH-4005
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15667894
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(973)596-0545
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	9735964500
<b>Email:</b>	IPDocket@gibbonslaw.com
<b>Correspondent Name:</b>	SAMUEL H. MEGERDITCHIAN
<b>Address Line 1:</b>	ONE GATEWAY CENTER
<b>Address Line 4:</b>	NEWARK, NEW JERSEY 07102-5310
<b>ATTORNEY DOCKET NUMBER:</b>	104610-90622 CON
<b>NAME OF SUBMITTER:</b>	SAMUEL H. MEGERDITCHIAN
<b>SIGNATURE:</b>	/Samuel H. Megerditchian/
<b>DATE SIGNED:</b>	08/08/2017
<b>Total Attachments: 2</b>	
source=assignment-pat-42251-173#page2.tif	
source=assignment-pat-42251-173#page3.tif	

**ASSIGNMENT**

WHEREAS, WE,

Johannes Laurenz **KELLENBERGER**, residing at Holweg 7, Riehen, CH-4125, Switzerland; and

Jürg **DREIER**, residing at Weisskirchweg 2, Witterswil, CH-4108, Switzerland,

(Assignors) have invented certain new and useful improvements which are described and claimed in United States Patent Application entitled

**Selected Macrolides With PDE4-Inhibiting Activity**

which claims priority of International Patent Application Serial No.: PCT/EP2013/078040 filed December 27, 2013, which claims priority from European Application Nos.: 12199801.7 filed December 31, 2012 and 13158812.1 filed March 12, 2013.

WHEREAS,

**Basilea Pharmaceutica AG,**

a corporation having its principal place of business at Grenzacherstrasse 487, CH-4005 Basel, Switzerland, (Assignee), is desirous of acquiring the entire interest in and to said invention, said applications and all patents to be obtained therefrom.

NOW, THEREFORE, for and in consideration of valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, we have sold, assigned, and set over, and by these presents do hereby sell, assign and set over unto the said

**Basilea Pharmaceutica AG,**

(Assignee), and said Assignee's legal representatives, successors, the entire right, title and interest, for the whole world, in and to said invention and said applications, as well as any subsequent application which claims priority based upon the filing date of any of said applications identified and the patents, both domestic and foreign, that may or shall result therefrom including the right to claim in respect of any subsequent United States and foreign patent applications and patents, the priority date of any of said applications under any United States statute and international convention or treaty; and we do hereby authorize and request the issuance of said patents, domestic and foreign, conformably to the terms of this Agreement.

UPON SAID CONSIDERATION, we do hereby covenant and agree with said Assignee that we will not execute any writing or do any act whatsoever conflicting with

these presents, and that will at any time upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings and so such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining provisional, original, continuation, continuation-in-part, divisional, reissued, re-examined or extended patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, including but not limited to, giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, we have hereunto set our hands and affixed our seals this day of 25 July, 2015.

25 July 2015  
Date

[Signature]  
Johannes Laurenz KELLENERGER

25 July 2015  
Date

[Signature]  
Jürg DREIER

Witness signature  
[Signature]  
Full Name: Malcolm G. P. Page

#2229868 v1  
104610-90622